Henry Schein, Inc. (NASDAQ:HSIC), the globally recognized provider of healthcare products and services, has seen significant activity lately. Although the company's stock underperformed when compared to competitors, it was tagged as a strong value and top momentum stock for the long-term. High profile bodies like
Norges Bank and
Corient Private Wealth LLC have purchased new stakes and increased holdings respectively in Henry Schein, underlining investor optimism. However, other ventures such as Brown Advisory Inc. and Vanguard Personalized Indexing Management LLC cut their stakes. Despite minor drawbacks, HSIC reported solid Q1 2024 earnings amidst various challenges. Analysts also predict Q3 2024 earnings to reach $1.35 per share. Innovations like Henry Schein's entrance to the orthopedic market with new buyouts and bolstering dental practices with AI tools have been noteworthy developments. Acquisitions, like the majority interest in TriMed, Inc, however, haven't met economic weight, causing some skepticism. Insider actions revealed Henry Schein's Vice Chairman and President, James Breslawski, selling 2,907 shares of the company. A notable cybersecurity incident also cast a shadow on the company's Q4 performance. Nonetheless, HSIC's focus remains on continual growth, with significant plans for investor conferences in June 2024.
Henry Schein HSIC News Analytics from Sun, 15 Oct 2023 07:00:00 GMT to Thu, 30 May 2024 10:01:26 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -2
